Akademik Veri Yönetim Sistemi
Selçuk Tıp Dergisi, cilt.40, sa.2, ss.68-73, 2024 (Hakemli Dergi)
Aim: This study’s goal is to evaluate the safety and efficacy of bevacizumab (BEV )-based therapies in patients with metastatic cervical cancer (CC) using real-life data. Materials and Methods: This study constitutes a retrospective observational analysis. Patients diagnosed with metastatic CC who received BEV treatment in the Medical Oncology department between January 2012 and December 2022 were included in the study. Results: This study encompassed 40 patients, with a median age of 51 years (range: 21-78), and a median follow-up duration post-treatment of 16.6 months. Predominant metastatic sites included the lymph nodes 72.5% (n=29), peritoneum 55% ( n=22), lungs 35% (n=14), liver 22.5% (n=9) and bones 15%( n=6). Regarding treatment responses, 12.5% (n = 5) of patients achieved complete response , 45% (n = 18) achieved partial response, 17.5% (n = 7) had stable disaese, and 25% (n = 10) experienced disease progression. The median progression-free survival was found 8.5 months (95% CI: 6.838 – 10.295), and the median overall survival was 16.3 months (95% CI: 11.305 – 21.362). The presence of bone metastasis (p=0.024) and obesity (p=0.020) are statistically significant factors affecting survival outcomes. There were no statistically significant differences in survival outcomes due to several factors, including age, pathology classification, number of metastatic sites, tumor grade, initial staging, previous surgeries and radiotherapy before starting therapy, and the type of cytotoxic agents administered with BEV (p > 0.05). Conclusions: Metastatic CC has a challenging prognosis. Combinations of BEV with chemotherapy agents are effective and safe in the treatment of this patient group.